Biotech Giants Clash Over mRNA Vaccine Patents
German biotech firm CureVac has filed a lawsuit against Moderna in Delaware, alleging patent infringement of its mRNA technology in Moderna's COVID-19 vaccine, Spikevax. The case is among several patent disputes in the biotech sector as companies vie for royalties from successful COVID-19 vaccines.
CureVac, a German biotech company, has initiated legal proceedings against Moderna in Delaware federal court, asserting that Moderna's COVID-19 vaccine, Spikevax, infringes on CureVac's patents concerning messenger RNA (mRNA) technology.
The lawsuit claims Moderna improperly utilized CureVac's stabilization technology for fragile mRNA in its vaccines and seeks royalties from Spikevax sales. CureVac's move follows BioNTech's acquisition and subsequent separate patent lawsuit against Moderna earlier this year.
This legal action is part of a broader wave of high-stakes patent litigation in the biotech industry as companies aim for compensation for technologies used in lucrative COVID-19 vaccines. The ongoing legal battles include a suit Moderna filed against Pfizer and BioNTech in 2022.
(With inputs from agencies.)
ALSO READ
JetBlue Accused of 'Surveillance Pricing' in New Lawsuit
Supreme Court Clears Path for War Veteran's Lawsuit Against Government Contractor
Dutch Activists Challenge Shell in Landmark Climate Lawsuit
FBI Director Kash Patel Battles The Atlantic in $250 Million Defamation Lawsuit
Tesla Settles Fatal Crash Lawsuit: Speeding and Safety Concerns Spotlighted
Google News